Human Immunodeficiency Virus Infection: Clinical Trials

4 completed. 4 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 4
Phase 2	1	Completed 1

Follow Human Immunodeficiency Virus Infection: new trials by email Literature Review of Human Immunodeficiency Virus Infection trials Research Report on Human Immunodeficiency Virus Infection

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine - Diphtheria, Tetanus	Phase 3	Completed	Sanofi Pasteur, a Sanofi Company	53	2016-07-14	2022-04-05
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection	Phase 3	Completed	AbbVie	153	2016-05-17	2021-07-13
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection ABT-450/r/ABT-267, ABT-333, ribavirin - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection	Phase 2 / Phase 3	Completed	AbbVie	318	2013-08-30	2021-07-12
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL) - Human Immunodeficiency Virus Infection	Phase 3	Completed	Abbott	206	2008-07-01	2012-02-14

Narrower conditions

Acquired Immunodeficiency Syndrome (4)  ·  Hepatitis C (2)  ·  Hepatitis C, Chronic (2)  ·  Diphtheria (1)  ·  HIV Infections (1)  ·  Hepatitis B (1)  ·  Infections (1)  ·  Poliomyelitis (1)  ·  Tetanus (1)  ·  Whooping Cough (1)

Broader conditions

Blood-Borne Infections (4)  ·  Communicable Diseases (4)  ·  Genital Diseases (4)  ·  Immune System Diseases (4)  ·  Immunologic Deficiency Syndromes (4)  ·  Lentivirus Infections (4)  ·  RNA Virus Infections (4)  ·  Retroviridae Infections (4)  ·  Sexually Transmitted Diseases (4)  ·  Sexually Transmitted Diseases, Viral (4)  ·  Slow Virus Diseases (4)  ·  Urogenital Diseases (4)  ·  Virus Diseases (4)  ·  Digestive System Diseases (3)  ·  HIV Infections (3)

Interventions

DTaP-IPV-HB-PRP-T vaccine (1)  ·  Emtricitabine (1)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Lopinavir (1)  ·  Raltegravir Potassium (1)  ·  Ribavirin (1)  ·  Tenofovir (1)  ·  dasabuvir (1)  ·  glecaprevir (1)  ·  glecaprevir and pibrentasvir (1)  ·  lopinavir-ritonavir drug combination (1)  ·  ombitasvir (1)  ·  paritaprevir (1)  ·  pibrentasvir (1)

Sponsors

AbbVie (2)  ·  Abbott (1)  ·  Sanofi Pasteur, a Sanofi Company (1)

Countries

Canada (1)  ·  France (1)  ·  Italy (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  South Africa (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Rolando Viani, MD (1)  ·  Thomas J Podsadecki, MD (1)

Results publications

PMID 22180523, PMID 22730929, PMID 26743093, PMID 27919899, PMID 28412293, PMID 30529905, PMID 30868245, PMID 30977945

NIH funding

2008 (1), 2015 (1), 2018 (1)